Search results
Results from the WOW.Com Content Network
Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.
Tumefactive Multiple sclerosis: lesions whose size is more than 2 cm, with mass effect, oedema and/or ring enhancement [9] [10] AntiMOG associated encephalomyelitis: Lesions similar to ADEM sometimes and to NMO some others. It is not normal, but can also appear like MS even with biopsy. These cases resemble MS pattern-II lesions. [11]
Marburg acute multiple sclerosis, also known as Marburg multiple sclerosis or acute fulminant multiple sclerosis, is considered one of the multiple sclerosis borderline diseases, which is a collection of diseases classified by some as MS variants and by others as different diseases.
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process.
Uhthoff's phenomenon (also known as Uhthoff's syndrome, [1] Uhthoff's sign, [1] and Uhthoff's symptom) is the worsening of neurologic symptoms in multiple sclerosis (MS) and other demyelinating diseases when the body is overheated.
Radiologically isolated syndrome (RIS) is a clinical situation in which a person has white matter lesions suggestive of multiple sclerosis (MS), as shown on an MRI scan that was done for reasons unrelated to MS symptoms.
Oligoclonal bands are an important indicator in the diagnosis of multiple sclerosis.Up to 95% of all patients with multiple sclerosis have permanently observable oligoclonal bands [15] at least for those with European ancestry. [16]
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva.It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.